News & Analysis on Clinical Trial Services & Contract Research And Development
By Melissa Fassbender
- Last updated on
Four senior executives were added to Certara’s Simcyp division, which provides mechanistic modeling technologies to inform drug development, including physiologically-based pharmacokinetic (PBPK), quantitative systems pharmacology (QSP), and quantitative systems toxicology and safety (QSTS) approaches.
Rob Aspbury, PhD, joins as chief operating officer, bringing more than 17 years’ commercial and scientific leadership experience with Covance.
Frederic Yves Bois, PharmD, PhD, is the division’s new senior scientific advisor and head of mechanistic modeling. He was previsouly the research director at the French National Institute for Industrial Environment and Risks (INERIS) and has consulted with the US FDA, EPA and OSHA, the European Commission, and the French Ministry of the Environment.
Joining Certara from AstraZeneca R&D in Cambridge (UK), where he was principal scientist for safety and mechanistic pharmacology, Will Redfern, PhD, is now the vice president of quantitative systems toxicology and safety at Certara.
Noriko Okudaira, PhD, will support clients locally in Japan as a senior consultant and scientific advisor. She joins certara from Daiichi Sankyo where she was the director of the clinical pharmacology department.